Doctor Unveils Revolutionary Immunotherapy Treatment For Late-Stage Cancers

19 Dec 2019 Cancer, Press Releases

Dr. Jason R. Williams unveils a revolutionary approach to intra-tumoral immunologic tumor elimination of advanced cancers

directly injecting into the tumor[National Harbor, Maryland]: Dr. Jason R. Williams of the Williams Cancer Institute announced a revolutionary approach to intra-tumoral immunologic tumor elimination of advanced cancers, unveiled at the 34th annual conference of the Society For Immunotherapy Of Cancer. The conference seeks to provide improved cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy across the medical field. Dr. Williams’s announcement is a major milestone for the Williams Cancer Institute on its mission to further advance research in intratumoral immunotherapy and help cancer patients.

The recently unveiled revolutionary approach allows for a greater combination of immunotherapy by directly injecting into the tumor, and has shown astounding results in a trial involving a stage-4 breast cancer patient with liver and a  single brain metastasis.

According to the presentation – a CT-guided injection was performed on the metastasis, containing a combination of immunotherapy agents suspended in Montanide ISA51. After the procedure, the team conducted a CT scan that according to Dr. Williams “demonstrated a complete resolution of liver masses.” A followup scan performed 9 months after the therapy showed additional results with the MRI showing no evidence of brain lesions.

The study, presented alongside the revolutionary approach suggests that immunotherapy placed directly into the tumor microenvironment is expected to activate the immune system locally and create an abscopal effect that can result in the complete elimination of cancer. This is attributed to harnessing the potential of the immune system to recognize and destroy malignant cells which would otherwise harbor tumor antigens. Dr Williams went on to suggest that this groundbreaking approach could revolutionize the treatment procedures and expected outcomes for challenging late-stage cases.

Patients with stage 4 cancer have been traditionally deemed incurable, regardless of the origin of the primary lesion. A complete recovery is a rare exception rather than the rule, due to disseminated cancer’s remarkable resilience to modern conventional treatment options,” says Dr. Jason R. Williams, Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute. “When you have cancer, you don’t have time to wait for today’s scientific advances to become standard treatment years from now, you need those today. At Williams Cancer Institute, we strive to bring you the treatments of the future, today.”

 

This news comes in the wake of many recent initiatives and accomplishments, including:

  • Winning the 2019 Vince Lombardi Cancer Foundation “Leaders For A Cure” award.
  • Dr. Jason R. Williams publishing the best-selling “The Immunotherapy Revolution” title.
  • Performing the first intratumoral OX40/CpG agonist procedure on a human in 2018.

 

While immunotherapy in itself is not a new or ground-breaking approach to cancer treatment, according to the presentation, it is a much safer, costefficient and in some cases effective approach by comparison to approach. It was noted that such a conventional systematic and aggressive treatment of cancer has been shown to leave the patient’s body in a weakened, susceptible sate, open to contracting other diseases or relapses. “Most of the medical field refuses to acknowledge the major problems with the way they treat cancer,” remarked Dr. Williams.

 

The presentation also noted that it is well known that for immunotherapy to be more effective, combinations will be necessary. However, these combinations, when given systemically, could result in significant autoimmune issues and some traditionally used agents may not be appropriate for systemic use. The proposed approach to intra-tumorous immunotherapy is set to solve these problems and may prove to be a more cost-effective and safe treatment option for patients.

In the presented study, the approach applied to the case of a patient suffering from stage-4 breast cancer with liver and a single brain metastasis was shown to have resolved the liver metastases and astoundingly, a brain metastases, as well.

“I believe that this strongly supports the need for further research in the area of intratumoral immunotherapy” concluded Dr. Williams in an interview set after the presentation.

To learn more about the revolutionary immunotherapy treatment for late-stage cancers alongside Dr. Williams’s research and practice, visit: Immunotherapy Procedures.

 

About Williams Cancer Institute: The Williams Cancer Institute is focused on advancing the use of intratumoral immunotherapy and helping late-stage cancer patients find a safer, less painful and more effective approach to treating cancer. With two operating facilities – an imaging centre in Atlanta, GA and a full-service hospital in Mexico City, Mexico the Williams Cancer Institute provides both in-patient and out-patient procedures and services for an international patient-base. Founded by Dr. Jason R. Williams, the institute has been a leading force at the forefront of development, research and applicational standardization of immunotherapy cancer treatment.

Doctor Wins 2019 Award For Alternative Cancer Treatment Releases Bestselling Immunotherapy Book

22 Oct 2019 Press Releases

Dr. Jason R. Williams wins 2019 Vince Lombardi Cancer Foundation Award and releases bestselling book: The Immunotherapy Revolution

Dr. Jason R. Williams has already achieved big things in 2019. He was nominated for the Vince Lombardi Cancer Foundation Leaders for a Cure Award for his excellence in advanced alternative cancer treatments “ and won the honor in January 2019. The patient of Dr. Williams responsible for the award nomination said, Dr. Williams not only saved my life. He saved my body from being cut up and poisoned beyond repair. If anyone deserved this award  it’s Dr. Williams.

Read More

Using temperature to awaken immune response to fight brain cancer

14 Oct 2019 Cancer

This certainly may apply to many cancers, as unfortunately, most are immunologically “cold,” which is why the current FDA approved immunotherapies fail in the majority of cases. There are numerous techniques to turn “cold” tumors to “hot.” Among these are injection into a tumor TLR agonist, STING agonist, CD40 agonist, and Oncopore peptides, to name a few. This article discusses using ultrasound to control temperature. The surprising aspect was it was not necessarily heating things up, like hyperthermia, but keeping the temperature stable. A very interesting and unexpected conclusion.

There is also a nice animation explaining the immune response to cancer and how cancer can evade the immune system.

Source: Labroots

Photo: Pixabay

Antibiotic use before cancer treatment cuts survival time study

4 Oct 2019 Cancer, Immunotherapy

We have discussed this before. It is becoming standard in our patients to not only evaluate the microbiome with Microbiome Dx, but also patients with recent antibiotic use prior to immunotherapy probably will need a fecal microbiota transplant (FMT).

Taking antibiotics in the month before starting immunotherapy dramatically reduces a cancer patient’s chances of survival, according to a small but groundbreaking study.

Scientists at Imperial College London believe antibiotics strip out helpful bacteria from the gut, which weakens the immune system. This appears to make it less likely that immunotherapy drugs will boost the body’s cancer-fighting capability.

Click here to continue reading

Source : https://amp.theguardian.com/society/2019/sep/12/antibiotic-use-before-cancer-treatment-cuts-survival-time-study?fbclid=IwAR0R9gSLfPW5nh1AKIloHHuYgYM6kFQpt2aEnYV9HZWR15EuVFn31Jg7F9E

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

2 Sep 2019 Immunotherapy

There are numerous reasons for immunotherapy to fail or for cancer in general to be able to fight against your body and survive. One important mechanism is Myeloid Derived Suppressor Cells (MDSC). These are immune cells that can actually protect cancer. As described in this article, a new method to target these using a drug that is already FDA approved (Mylotarg) can enhance the success of immunotherapy such as immune check-point inhibitors (Keytruda, Opdivo, Yervoy) and also CAR-.

More on https://www.sciencedirect.com/science/article/pii/S235239641930547X?via%3Dihub&amp=1&fbclid=IwAR1b1xMRrG8JeUe7GyI8UBfws8oED40RVwtFV5L1HRIFg_TgFW7QPnaqmjY

The Immunotherapy Revolution: The Best New Hope For Saving Cancer Patients

28 Aug 2019 Book

Stay tuned for the release of The Immunotherapy Revolution: The Best New Hope For Saving Cancer Patients Lives by the incredible Dr. Jason Williams from the Williams Cancer Institute.

This book is a must read for all cancer patients.

If you are interested in, or are already getting immunotherapy for cancer, this book is your guide to boosting the response and beating cancer.

Visit www.immunotherapyrevolution.com for more information.

How is Immunotherapy Changing the Outlook for Patients with Breast Cancer?

9 Aug 2019 Cancer

Breast cancer is one of the most commonly diagnosed cancer types among women globally. Globally, there were an estimated 2.1 million new cases of breast cancer and 630,000 deaths due to breast cancer in 2018. In the United States alone, there were an estimated 270,000 cases of breast cancer diagnosed in 2018 along with 41,000 deaths, and approximately 1 in 8 women and about 1 in 1,000 men will develop invasive breast cancer at some point in their lives. Thus, the need for effective, lasting breast cancer treatment is urgent.

Increased risk for breast cancer is associated with a personal or family history of the disease and inherited genetic mutations in breast cancer susceptibility genes. These include BRCA1 and BRCA2 and other less common inherited gene mutations. An inherited predisposition to develop breast cancer accounts for approximately 5%-10% of all breast cancer cases, but is rare in the general population (less than 1%). Women with BRCA1 and BRCA2 mutations have an estimated 45% to 65% higher risk of developing breast cancer by age 70, though the risk is highest around age 40. People with these mutations should discuss their risk with a genetic counsellor. Other known risk factors include obesity, use of MHT (a hormone therapy that combines progestin and estrogen), high breast tissue density, alcohol consumption, and physical inactivity.

Current methods for breast cancer treatment typically involve surgery if the disease is diagnosed early. Depending on the stage and molecular characteristics of the cancer when diagnosed, breast cancer surgery may be followed by additional chemotherapy, radiation, or targeted therapies, including hormone therapy.

Although breast cancer has long been regarded as difficult to treat with immunotherapy because it is immunologically cold, several newer preclinical and clinical studies now suggest that immunotherapy treatment has the potential to improve outcomes for breast cancer patients.

In March 2019, the FDA approved the first checkpoint inhibitor immunotherapy drug, an anti-PD-L1 antibody called atezolizumab, (Tecentriq®), in combination with chemotherapy, for the treatment of triple-negative, metastatic breast cancer in patients whose tumors express the PD-L1 protein.

Source: https://www.cancerresearch.org/immunotherapy/cancer-types/breast-cancer

Breast Cancer Cryoablation. The future of breast cancer treatment. Contact us today! 251-943-9409

A poor gut microbiome could cause breast cancer to spread

New research from the University of Virginia Cancer Center and recently published in the journal Cancer Research suggests that an unhealthy gut microbiome could result in the spread of breast cancer throughout the body.

The research was spearheaded by Melanie Rutkowski, PhD, of UVA’s Department of Microbiology, Immunology and Cancer Biology. Dr. Rutkowski used mice to show how an unhealthy gut caused breast cancer to become much more aggressive, leading it to disseminate to other parts of the body.

“When we disrupted the microbiome’s equilibrium in mice by chronically treating them antibiotics, it resulted in inflammation systemically and within the mammary tissue,” Dr. Rutkowski explains. “In this inflamed environment, tumor cells were much more able to disseminate from the tissue into the blood and to the lungs, which is a major site for hormone receptor-positive breast cancer to metastasize.”

“Disrupting the microbiome resulted in long-term inflammation within the tissue and the tumor environment, “Rutkowski said.” These findings suggest that having an unhealthy microbiome, and the changes that occur within the tissue that are related to an unhealthy microbiome, may be early predictors of invasive or metastatic breast cancer. Ultimately, based upon these findings, we would speculate that an unhealthy microbiome contributes to increased invasion and a higher incidence of metastatic disease.”

However, Rutkowski is quick to reassure that the use of antibiotics in human women should not be enough to disrupt a women’s microbiome to the extent that she was with the mice in her research. Instead, she says, her methods utilized antibiotics as a means to disrupt the microbiomes of the mice and simulate what an unhealthy biome looks like, so as to determine its influence on the spread of breast cancer. Women with breast cancer should not, she says, refrain using antibiotics if needed to treat an infection just because of her study’s results.

The take-home message from Dr. Rutkowskiâ’s research is how crucial a healthy microbiome is, not just to prevent the spread of breast cancer, but for overall good health.

Source: Labroots

Novel protocol improves pancreatic cancer outcomes

6 Jun 2019 Cancer

Combination of radiation, chemo, and blood-pressure drug losartan extends patient survival.

Locally advanced pancreatic cancer (LAPC) a tumor that, while still confined to the pancreas, involves major abdominal blood vessels is one of the worst forms of an already deadly tumor, as it cannot be removed surgically. Now a Massachusetts General Hospital (MGH) Cancer Center clinical trial of a treatment protocol combining intensive chemotherapy and radiation with the blood-pressure drug losartan has produced unprecedented results, allowing complete removal of the tumor in 61 percent of participants and significantly improving survival rates.

Around 40 percent of pancreatic cancer patients have either locally advanced or borderline resectable disease, with historically poor rates of successful surgery, said Janet Murphy, an instructor in medicine in the hematology/oncology division of Mass. General’s Department of Medicine, co-lead and corresponding author of the report in JAMA Oncology. To be able to successfully remove the primary tumor in 61 percent of patients sets a new benchmark and offers much hope. To our knowledge, this is the first LAPC clinical trial that defined surgical success as its primary outcome.

The most novel element of the trial use of the antihypertension drug losartan builds on the findings of co-author Rakesh K. Jain, director of the Steele Laboratories for Tumor Biology at MGH and Andrew Werk Cook Professor of Radiation Oncology at Harvard Medical School, and his colleagues. Those studies found that losartan, which targets the angiotensin signaling pathway, improved the delivery of chemotherapy drugs in animal models of breast, pancreatic, and ovarian cancer. It does so by relieving pressures in the tumor microenvironment that physically block drug delivery and reduce the supply of oxygen, which is required for the tumor-killing effects of radiation therapy. Those studies also found that cancer patients who happened to be taking losartan or similar drugs for hypertension tended to live longer than others receiving the same sorts of cancer therapies.

From August 2013 through July 2017 the study enrolled 49 MGH Cancer Center patients with previously untreated LAPC. All participants received chemotherapy with a combination of fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) over a four-month period, during which they also took daily doses of losartan. After CT scan evaluation to determine whether blood vessels were still involved in the tumors, patients who no longer had vascular involvement received a short course of proton-beam radiation therapy, while those whose tumors still included major blood vessels had a longer course of conventional radiation therapy. Both groups received capecitabine chemotherapy during this period.

After completing the chemoradiotherapy stage, 34 of the 49 participants were able to have their tumors removed, with 30 of those procedures successfully eliminating all evidence of cancer around the tumor. A pathologic complete response which signifies no tumor found anywhere was achieved for three patients. Analysis of circulating biomarkers throughout the course of the study found significant drops in the expression of TGF-β, a key element in the angiotensin-signaling pathway, indicating that losartan was having its desired effect. Both the time until recurrence and the overall survival time were significantly longer than what previously had been seen in LAPC patients.

A key part of the success of our approach was our surgeons willingness to attempt an operation even in patients who had the appearance of cancer at or near their blood vessels, said Murphy. We learned in a previous study, confirmed here, that CT scan results and resectability are no longer clearly correlated after chemotherapy and radiation. While we did not see total blood vessel clearance in 61 percent of patients, 61 percent achieved a complete removal of their cancer.

lead author Jennifer Wo, an assistant professor of radiation oncology, adds, Locally advanced pancreatic cancer has been generally considered an incurable disease, so these results mark a dramatic improvement with respect both to rates of conversion to surgical resectability and to long-term disease outcomes. Based on these results we have launched a new, multi-institutional clinical trial that will also include the immunotherapy drug nivolumab, since losartan treatment has also been shown to activate several immune-system pathways.

The co-senior authors of this report are Theodore Hong, MGH Radiation Oncology, and Carlos Fernández-del Castillo, MGH Department of Surgery.

Resources: https://news.harvard.edu/gazette/story/2019/05/mass-general-trial-shows-novel-protocol-improves-pancreatic-cancer-outcomes/?fbclid=IwAR3YSzZDHBIxFP9R4myontRlp4VCG4gjuEuOP0C3lvt09CTYlct5A8xiiuM

Is Immunotherapy for Cancer Safe?

Your immune system does more than simply fight colds and flu. Throughout your life, your natural defenses seek out and destroy anything that is not recognized as part of the self including all kinds of germs and cancer cells before they have a chance to cause disease. Your immune system manages to destroy most rogue cells before they form a full-fledged tumor, but some of them get by your defenses. If you already have cancer, your immune system will still be working hard to keep your disease in check, but it probably can’t do the job on its own.

In recent years, more and more cancer patients have received treatments designed to give the immune system the upper hand against cancer. This approach called immunotherapy or biological therapy isn’t as widely used as radiation or chemotherapy. For most types of cancer, immunotherapy hasn’t been shown to be more effective than these standard treatments. And like the others, it can cause its own unpleasant side effects.

But immunotherapy can still be a powerful tool, either on its own or combined with chemotherapy or radiation. For certain patients including some in the advanced stages of skin cancer or kidney cancer immunotherapy can offer more than the conventional options, even the possibility of a complete cure. For others, it’s an additional, less toxic method of controlling their disease or reducing side effects from other treatments. In the years to come, as scientists learn more about the immune system, immunotherapy promises to become even more common and more effective.

What does it involve?

Immunotherapy often involves adding more immune cells, immune signaling molecules, or other biochemicals to the body. Unlike chemotherapy, which affects all fast-growing cells, immune treatments target specific processes or types of cells and should have a low impact on healthy tissues. The side effects depend on the particular biological agent used. Some have very mild side effects, while others cause serious problems.

The delivery will also depend on the agent used as well as your treatment plan. Some immunotherapy treatments are in the form of pills or shots you can take at home, while others are delivered intravenously (IV) in the hospital or clinic. Immunotherapy may be administered a couple of times a day or as seldom as every month or two.

What are the different types of immunotherapy?

There are two major types of immunotherapy: Treatments that add new disease-fighting cells to your body (T cells) and treatments that add other elements to your own immune system (such as antibodies, cytokines, and others). Many immunotherapy agents are experimental or investigational and are only available by enrolling in clinical trials.

How will my doctor decide if immunotherapy is right for me?

Not all patients or all cancers are good candidates for immunotherapy. At this time, the approach isn’t used very often for patients with cancer of the prostate or ovaries. And if your cancer was caught at an early stage or is responding well to other treatments, immunotherapy may simply not be necessary.

In certain cases, however, immunotherapy does seem to be more effective when used for some smaller, earlier-stage cancers. If your doctor does recommend immunotherapy, you will be getting a cutting-edge treatment that could make a big difference.

Call Us now to know if you are a candidate.

References

American Cancer Society. What is immunotherapy? October 2010.
American Cancer Society. Types of immunotherapy. October 2010.
National Cancer Institute. Biological therapies for cancer. Questions and answers. 2006.

1 2

Search

+